FI972225A - Vektorit kudosspesifistä replikaatiota varten - Google Patents

Vektorit kudosspesifistä replikaatiota varten Download PDF

Info

Publication number
FI972225A
FI972225A FI972225A FI972225A FI972225A FI 972225 A FI972225 A FI 972225A FI 972225 A FI972225 A FI 972225A FI 972225 A FI972225 A FI 972225A FI 972225 A FI972225 A FI 972225A
Authority
FI
Finland
Prior art keywords
vectors
tissue
vector
replication
gene
Prior art date
Application number
FI972225A
Other languages
English (en)
Swedish (sv)
Other versions
FI972225A0 (fi
Inventor
Paul L Hallenbeck
Yung-Nien Chang
Yawen L Chiang
Original Assignee
Genetic Therapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Therapy Inc filed Critical Genetic Therapy Inc
Publication of FI972225A0 publication Critical patent/FI972225A0/fi
Publication of FI972225A publication Critical patent/FI972225A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI972225A 1994-11-28 1997-05-26 Vektorit kudosspesifistä replikaatiota varten FI972225A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34825894A 1994-11-28 1994-11-28
US48799295A 1995-06-07 1995-06-07
PCT/US1995/015455 WO1996017053A1 (en) 1994-11-28 1995-11-28 Vectors for tissue-specific replication

Publications (2)

Publication Number Publication Date
FI972225A0 FI972225A0 (fi) 1997-05-26
FI972225A true FI972225A (fi) 1997-07-16

Family

ID=26995620

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972225A FI972225A (fi) 1994-11-28 1997-05-26 Vektorit kudosspesifistä replikaatiota varten

Country Status (10)

Country Link
EP (1) EP0791050B1 (fi)
JP (1) JPH10509880A (fi)
AT (1) ATE317895T1 (fi)
AU (1) AU716045B2 (fi)
CA (1) CA2206179C (fi)
DE (1) DE69534791T2 (fi)
ES (1) ES2258265T3 (fi)
FI (1) FI972225A (fi)
NO (1) NO972373L (fi)
WO (1) WO1996017053A1 (fi)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US7001764B2 (en) 1995-06-27 2006-02-21 Cell Genesys, Inc. Compositions comprising tissue specific adenoviral vectors
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
AU5253998A (en) * 1996-11-13 1998-06-03 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
EP1905837A1 (en) * 1997-03-03 2008-04-02 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
AU744725B2 (en) * 1997-03-03 2002-02-28 Cold Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
EP1918380A3 (en) * 1997-03-03 2008-08-06 Cell Genesys, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6432700B1 (en) * 1997-03-03 2002-08-13 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
AU745600B2 (en) * 1997-03-03 2002-03-21 Cell Genesys, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
WO1998039467A2 (en) * 1997-03-03 1998-09-11 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
ATE540686T1 (de) * 1999-05-12 2012-01-15 Uab Research Foundation Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
WO2001023004A1 (en) * 1999-09-30 2001-04-05 The Trustees Of The University Of Pennsylvania Replication selective adenoviruses for use in cancer therapy
AU785483B2 (en) 1999-12-10 2007-09-20 Invitrogen Corporation Use of multiple recombination sites with unique specificity in recombinational cloning
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP2105496B1 (en) 2000-12-08 2013-02-20 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
ES2634424T3 (es) 2002-02-01 2017-09-27 Oxford Biomedica (Uk) Limited Vector multicistrónico lentivírico
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
US7371570B2 (en) 2002-11-01 2008-05-13 Cell Genesys, Inc. Cell-specific adenovirus vector comprising EBV-specific promoter
US7026164B2 (en) 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
EP1670925B1 (en) 2003-10-02 2013-05-01 Crucell Holland B.V. Packaging cells for recombinant adenovirus
US7482156B2 (en) 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
DE602004027538D1 (de) 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
JPWO2011074564A1 (ja) * 2009-12-15 2013-04-25 タカラバイオ株式会社 アデノウイルスベクターの製造方法
AU2013211871B2 (en) 2012-01-25 2017-12-14 Board Of Regents, The University Of Texas System Biomarkers and combination therapies using oncolytic virus and immunomodulation
NZ628213A (en) 2012-02-02 2016-10-28 Univ Texas Adenoviruses expressing heterologous tumor-associated antigens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112767A (en) * 1988-03-04 1992-05-12 University Of Southern California Vectors with enhancer domains
US5416017A (en) * 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters
NL9001828A (nl) * 1990-08-15 1992-03-02 Centraal Diergeneeskundig Inst Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde.
DK0931830T3 (da) * 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi

Also Published As

Publication number Publication date
EP0791050A4 (en) 2001-09-05
CA2206179A1 (en) 1996-06-06
AU716045B2 (en) 2000-02-17
CA2206179C (en) 2007-10-23
NO972373D0 (no) 1997-05-23
ATE317895T1 (de) 2006-03-15
DE69534791T2 (de) 2006-08-31
ES2258265T3 (es) 2006-08-16
FI972225A0 (fi) 1997-05-26
DE69534791D1 (de) 2006-04-20
EP0791050A1 (en) 1997-08-27
WO1996017053A1 (en) 1996-06-06
AU4504396A (en) 1996-06-19
NO972373L (no) 1997-07-25
JPH10509880A (ja) 1998-09-29
EP0791050B1 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
FI972225A0 (fi) Vektorit kudosspesifistä replikaatiota varten
ATE330019T1 (de) Vektor zur gewebespezifischen replikation und expression
DE69534878D1 (de) Neuartige adenovirale vektoren, verpackungsszellinien, rekombinante adenoviren und verfahren
FI951404A0 (fi) Adenovirusvektoreita vieraiden geenien siirtämiseksi keskushermostojärjestelmän, erityisesti aivojen, soluihin
IL122120A (en) Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome
NO961639L (no) Rekombinant adenovirusvektor og fremgangsmåte for anvendelse derav
DK0698108T3 (da) Adenovirale vektorer af animalsk oprindelse og deres anvendelse ved genterapi
DE69636863D1 (de) Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
HUT68379A (en) Method for modifying the cell, tissue or host tropism of a recombinant microorganism obtained this way and use thereof in medicine and veterinary medicine
HUP9802587A2 (hu) Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
MY119381A (en) Recombinant mva virus, and the use thereof
MY134484A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
MA Patent expired